Novel compounds and their use as positive AMPA receptor modulators
申请人:Neurosearch A/S.
公开号:US20040043987A1
公开(公告)日:2004-03-04
The invention provides novel compounds represented by the general formula 5 compound represented by the formula:
1
wherein
the bond represented by the broken line may be a single, a double bond or absent;
and if the bond is absent, then the nitrogen is substituted with a hydrogen and R
2
;
X represents SO
2
or C═O or CH
2
;
Y represents —CH(R
4
)—, —N(R
4
)— or —N(R
4
)—CH
2
—, O;
and the meaning of R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, and R
8
are as defined in the application
The compounds are useful as positive modulators of the AMPA-receptor.
[EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
申请人:ORIGENIS GMBH
公开号:WO2014060113A1
公开(公告)日:2014-04-24
The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.
[EN] PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
申请人:ORIGENIS GMBH
公开号:WO2014060112A1
公开(公告)日:2014-04-24
The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.
[EN] 2,4-DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS<br/>[FR] 2,4-DI (PHENYLAMINO) PYRIMIDINES UTILES DANS LE TRAITEMENT DE TROUBLES PROLIFERATIFS
申请人:NOVARTIS AG
公开号:WO2005026130A1
公开(公告)日:2005-03-24
There is provided a method of preventing or treating proliferative disorders such as a tumor disease, by inhibiting ALK activity with compounds of formula (I) wherein X, R1, R2 , R3 , R4 , R5, R6, R7,R8 and R9 are as indicated in claim 1.
There are provided compounds of formula I
Wherein X, R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
and R
9
are as indicated in claim
1,
useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK.